322 related articles for article (PubMed ID: 32793499)
1. The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells.
Cai WQ; Zeng LS; Wang LF; Wang YY; Cheng JT; Zhang Y; Han ZW; Zhou Y; Huang SL; Wang XW; Peng XC; Xiang Y; Ma Z; Cui SZ; Xin HW
Front Oncol; 2020; 10():1249. PubMed ID: 32793499
[TBL] [Abstract][Full Text] [Related]
2. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles.
Santos EDS; Nogueira KAB; Fernandes LCC; Martins JRP; Reis AVF; Neto JBV; Júnior IJDS; Pessoa C; Petrilli R; Eloy JO
Int J Pharm; 2021 Jan; 592():120082. PubMed ID: 33188892
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
Gridelli C; Maione P; Ferrara ML; Rossi A
Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
[TBL] [Abstract][Full Text] [Related]
5. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
[TBL] [Abstract][Full Text] [Related]
6. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
7. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
Snyder LC; Astsaturov I; Weiner LM
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
[TBL] [Abstract][Full Text] [Related]
8. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor as a target for chemotherapy.
Vallbohmer D; Lenz HJ
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
11. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
12. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Patel DK
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
[TBL] [Abstract][Full Text] [Related]
14. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
16. [Biotherapy of cancer by anti-EGFR monoclonal antibody].
Wang J; Meng ZY; Fu ST; Dou GF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1135-8. PubMed ID: 17956707
[TBL] [Abstract][Full Text] [Related]
17. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
Zhang W; Gordon M; Lenz HJ
Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
[TBL] [Abstract][Full Text] [Related]
18. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Zibelman M; Mehra R
Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
[TBL] [Abstract][Full Text] [Related]
19. [The current status of development of anti-EGFR antibodies].
Ura T
Gan To Kagaku Ryoho; 2010 May; 37(5):777-81. PubMed ID: 20495305
[TBL] [Abstract][Full Text] [Related]
20. Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer.
Takeda M; Okamoto I; Nishimura Y; Nakagawa K
Lung Cancer (Auckl); 2011; 2():59-67. PubMed ID: 28210119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
